Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) saw a 26% decline in attributable profit in the first nine months of 2025 to 256.2 million yuan from 344.1 million yuan in the year-ago period, a Friday filing with the Hong Kong bourse said.
Earnings per share fell to 0.37 yuan from 0.50 yuan previously.
Operating income jumped 0.4% to 6.76 billion yuan in the three quarters from 6.73 billion yuan a year prior.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.